Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women with Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy

BACKGROUND: Postmenopausal women with osteoporosis/osteopenia are at increased risk of fracture. Aromatase inhibitors further increase bone loss in these patients. This study evaluates whether zoledronic acid prevents the bone loss expected when these patients initiate letrozole. PATIENTS AND METHOD...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Hines, Stephanie L., Sloan, Jeff A., Atherton, Pamela J., Perez, Edith A., Dakhil, Shaker R., Johnson, David B., Reddy, Pavan S., Dalton, Robert J., Mattar, Bassam I., Loprinzi, Charles L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2010
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2854212/
https://ncbi.nlm.nih.gov/pubmed/20079640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2009.12.001
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak